Metabolix labeled a risky, speculative stock

In Seeking Alpha, the guide warns against investing in Metabolix for all but the most risk-tolerant investors. Claiming that the company is struggling to develop new sources of revenue, with a shrinking cash reserve and no financing for a new commercial-scale facility after the termination of its joint venture with DSM. The article also cites the turbulent price of the stock over the last year, pointing out repeated 50% swings up and down.

More on the story.